Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy, preliminary results on 100 patients
Tirelli U, Franzini M, Valdenassi L, et al. European Review for Medical and Pharmacological Sciences, 2021.
- Study type
- Cohort study
- People studied
- 100 people
- Population
- Patients with post-COVID fatigue
- Published
- 2021, European Review for Medical and Pharmacological Sciences
- Identifiers
- PMID 34604980, DOI 10.26355/eurrev_202109_26809
What the authors reported
In 100 patients with post-COVID fatigue, a preliminary, uncontrolled series of oxygen-ozone autohemotherapy reported reduced fatigue scores after treatment.
What limits this result
No comparison group, so how much of the change would have occurred anyway cannot be determined; preliminary results from ozone-therapy society-affiliated authors.
Other ozone methods, such as major autohemotherapy, that clinics cite in support of EBO2. A result for one method does not transfer automatically to another. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
Where we cite this study
EBO2 (EBOO) for Long COVID: What Has Been Studied
What NIH RECOVER, FDA enforcement action, and small ozone autohemotherapy trials actually show about EBO2 (also called EBOO) and long COVID symptoms.